SAN DIEGO, January 10, 2021 (GLOBE NEWSWIRE) – Bionano Genomics, Inc. (Nasdaq: BNGO) announces the launch of its five-day next-generation cytogenomics symposium, which begins on Monday, January 11 and features 33 presentations by distinguished Saphyr users from leading hospitals and medical research institutes around the world. The presentations will cover optical genomic mapping (GMO) applications with Saphyr to analyze the genomes of patients with a variety of genetic diseases, blood cancers, solid tumors and recurrent disorders, as well as the studies validating clinical trials developed by Saphyr users , supported. The last day of the symposium is dedicated to the study of the genomes of severely ill COVID-19 patients. The event is virtually being held and will conclude on January 15, 2021.
Alka Chaubey, FACMG, PhD, Chief Medical Officer of Bionano Genomics, said: ‘I joined Bionano Genomics in August 2020 because I believed Saphyr was finally ready to transform the way genomes are analyzed in cancer and genetic diseases. . I quickly realized that the research and clinical communities were not sufficiently aware of Saphyr’s capabilities as an informative tool to detect structural variants of clinical importance. We created this symposium as part of our efforts to change that. I believe this opportunity will be a turning point for Bionano Genomics as we demonstrate the remarkable capabilities of GMOs with Saphyr and how it has the potential to become a standard platform in the pathologist and researcher’s weaponry. “
Erik Holmlin, PhD, CEO of Bionano Genomics, said: “We have made tremendous progress over the past year in enhancing Saphyr’s capabilities to detect the different classes of large genomic variants relevant to cancer and genetic diseases with high throughput and low cost in a simple workflow. Important recent data will be presented during our symposium, which we believe shows that Saphyr can detect all clinically reported structural variants identified by traditional cytogenetic methods, which short-reading or long-reading sequence technology could not do. In addition to the parallelism of the methods that are standard of care, providers will illustrate how GMOs with Saphyr find additional variants missed by the traditional methods, which have led to the diagnosis of more patients and an increase in diagnostic yield. We are excited to show the global community how Saphyr enables the next generation of cytogenomics. ”
Each session lasts approximately 2.5 hours and begins at 7 a.m. PST. After the scientific presentations, the speakers will take part in a live panel discussion and questions and answers moderated by Bionano’s Chief Medical Officer Alka Chaubey. After the live event, the recordings will be made available for viewing on request.
Monday 11 January: Constitutional cytogenetics
This session begins with a presentation on Saphyr’s clinical validation studies compared to the standard of care cytogenetics for constitutional genetic diseases and prenatal testing. Additional speakers show how Saphyr can find pathogenic variants that cannot be detected by traditional methods for a variety of genetic diseases and facial developmental disorders.
Tuesday, January 12: Heme Malignancy
Eight speakers from around the world will present results of their studies comparing Saphyr to the cytogenetic standard of care for genome analysis of a variety of home malignancies, including MDS, adults and pediatric B-ALL and CLL leukemias, concluding with the presentation of the results of a large national multi-center evaluation on acute myeloid leukemia.
Wednesday 13 January: Solid crop
In this session, speakers will discuss their analysis of solid tumor genome structure in head and neck cancer, non-inflammatory and inflammatory breast cancer, liver cancer, uveal melanoma, and end with an update on the development of a cancer LDT with Saphyr.
Thursday 14 January: Complex molecular diagnosis
This session returns to genetic diseases with a focus on repeated expansions and contractions and other complex molecular mechanisms. Hear how Saphyr’s ultra-long DNA molecule imaging can measure recurrent contractions that cause FSHD, repeated extensions that cause spinocerebellar ataxia and familial myoclonic epilepsy in adults, and possibly solve other genetic mysteries.
Friday, January 15: Covid-19 host-genome SV expert panel session
Key members of the COVID-19 host SV consortium will tell how they use Saphyr and other genomics technologies to detect structural variants in the human genome that can lead to mild or severe COVID-19 diseases. Speakers will present about their study of 37 critically ill patients admitted by ICU, about children with MIS-C, about comparative genomics of SARS-CoV-2 susceptible animals and humans, and more.
The full schedule of speakers and access to registration is available at http://bit.ly/3pLPT28
About Bionano Genomics
Bionano is a genome analysis company providing tools and services based on its Saphyr system to scientists and clinicians conducting genetic research and patient testing and providing diagnostic tests for those with Autism Spectrum Disorder (ASS) and other neurodevelopmental disabilities through its Lineagen company. Bionano’s Saphyr system is a single research use platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostic and therapeutic targets and the study of changes in chromosomes, known as cytogenetics, to streamline. . The Saphyr system consists of a tool, consumables for chips, reagents and a range of data analysis tools, and genomic analysis services to provide access to data generated by the Saphyr system for researchers who prefer not to use the Saphyr system in their laboratories. Lineagen has been providing genetic testing services to families and their healthcare providers for more than nine years and has performed more than 65,000 tests for those with neurological problems. For more information, visit www.bionanogenomics.com of www.lineagen.com.
Forward-looking statements
This press release contains forward-looking statements within the meaning of the Private Securities Reform Act in 1995. Words such as ‘power’, ‘will’, ‘expect’, ‘plan’, ‘expect’, ‘estimate’, ‘intend’ and similar expressions (as well as other words or expressions referring to future events, circumstances or circumstances) convey uncertainty about future events or outcomes and are intended to identify these forward-looking statements. Forward-looking statements include statements about our intentions, beliefs, forecasts, prospects, analyzes or current expectations regarding, inter alia: the timing and content of the presentations identified in this press release; the effectiveness and usefulness of Bionano’s technology in basic genetic research and clinical settings, and in the contexts and applications identified by the presentations in this press release; the acceptance of Saphyr as a standard platform in research and pathological environments; and the execution of Bionano’s strategy. Each of these forward-looking statements carries risks and uncertainties. Actual results or developments may differ materially from what is projected or implied in these forward-looking statements. Factors that can cause such a difference include the risks and uncertainties associated with: the impact of the COVID-19 pandemic on our business and the global economy; general market conditions; changes in the competitive landscape and the introduction of competitive products; changes in our strategic and commercial plans; our ability to obtain sufficient funding to fund our strategic plans and commercialization efforts; the ability of medical and research institutions to obtain funding to support the adoption or continued use of our technologies; the loss of key executives and our commercial team; and the risks and uncertainties associated with our business and financial condition in general, including the risks and uncertainties described in our documentation with the Securities and Exchange Commission, including, without limitation, our annual report on Form 10-K for the year ended December 31, 2019 and in other submissions we later made to the Securities and Exchange Commission. All forward-looking statements in this press release apply only to the date it was made and are based on the assumptions and estimates of management from that date. We undertake no obligation to update future judgments in public, whether due to the receipt of new information, the occurrence of future events or otherwise.
CONTACTS
Company contact:
Erik Holmlin, CEO
Bionano Genomics, Inc.
+1 (858) 888-7610
[email protected]
Investor Relations Contact:
Ashley R. Robinson
LifeSci Advisors, LLC
+1 (617) 430-7577
[email protected]
Media contact:
Darren Opland, PhD
LifeSci Communication
+1 (617) 733-7668
[email protected]